-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GgrDbjTT7anFzPLZB6cDwOQM7UoIPRn4ndl1PtbL20CfSdFulBBQ4EoHhUVqFERc IKs4sch3SLDOusYX+sG/Kg== 0001279569-08-000568.txt : 20080506 0001279569-08-000568.hdr.sgml : 20080506 20080506123344 ACCESSION NUMBER: 0001279569-08-000568 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20080505 FILED AS OF DATE: 20080506 DATE AS OF CHANGE: 20080506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LORUS THERAPEUTICS INC CENTRAL INDEX KEY: 0000882361 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 FISCAL YEAR END: 0531 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32001 FILM NUMBER: 08805471 BUSINESS ADDRESS: STREET 1: 2 MERIDIAN ROAD STREET 2: . CITY: TORONTO STATE: A6 ZIP: M9W 4Z7 MAIL ADDRESS: STREET 1: 2 MERIDIAN ROAD CITY: TORONTO STATE: A6 ZIP: M9W 4Z7 FORMER COMPANY: FORMER CONFORMED NAME: IMUTEC PHARMA INC DATE OF NAME CHANGE: 19970113 FORMER COMPANY: FORMER CONFORMED NAME: IMUTEC CORP DATE OF NAME CHANGE: 19950726 FORMER COMPANY: FORMER CONFORMED NAME: RML MEDICAL LABORATORIES INC DATE OF NAME CHANGE: 19920921 6-K 1 lorus6k20250.htm FORM 6-K lorus6k20250.htm
 
 
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the Month of May, 2008
 
Commission File Number 1-32001

Lorus Therapeutics Inc.
(Translation of registrant’s name into English)


2 Meridian Road, Toronto, Ontario M9W 4Z7
(Address of principal executive offices)


Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
 
Form 20-F x      Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ¨      No x

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82-_______________.


 
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of  1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 
Lorus Therapeutics Inc. 
   
   
Date: May 5, 2008 
 By:  /s/ “Elizabeth Williams”
    Elizabeth Williams
    Director of Finance and Controller


 
EXHIBIT INDEX
 
99.1
News Release dated May 5, 2008 - Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions

 

 
 EX-99.1 2 ex991.htm NEWS RELEASE DATED MAY 5, 2008 - LORUS THERAPEUTICS STRENGTHENS ITS SENIOR MANAGEMENT TEAM THROUGH INTERNAL PROMOTIONS ex991.htm
 
EXHIBIT 99.1
 
News release via Canada NewsWire, Toronto 416-863-9350

	    Attention Business Editors:
	    Lorus Therapeutics Strengthens Its Senior Management Team Through
	    Internal Promotions

	    TORONTO, May 5 /CNW/ - Lorus Therapeutics Inc. ("Lorus") (TSX: LOR; AMEX:
LRP), a biopharmaceutical company dedicated in the research, development and
commercialization of pharmaceutical products and technologies for the
management of cancer, announced today that it has strengthened its senior
management team with the appointment of Dr. Saeid Babaei to Vice-President of
Business Development and Dr. Yoon Lee to Vice-President of Research. Both will
serve as members of Lorus' senior management team.
	    Dr. Babaei joined Lorus in 2006, where he has held the progressive
positions of Associate Director of Corporate Affairs and Director of Corporate
Development, and has played a key role in a broad range of activities
involving investor relations, business development and licensing strategies.
As Vice-President of Business Development, Dr. Babaei will have
responsibilities in planning, developing and implementing Lorus' business
development efforts and strategic partnerships. His multi-disciplinary
experience spans over fifteen years in the biotechnology and healthcare
sectors, during which he has negotiated strategic alliances and licensing
deals, established joint ventures and assisted in private financings to
support product development. Dr. Babaei received a PhD and an executive MBA,
both from the University of Toronto. He has authored many scientific
publications, patents and conference proceedings. He currently serves as a
member of the Board of Directors for several not-for-profit organizations.
	    Dr. Lee has been with Lorus for ten years, most recently serving as the
Director of Research. He has been responsible for overseeing research
discovery and product development programs, including anticancer
immunomodulators, DNA/RNA-based therapeutics and small molecules. As Vice-
President of Research, Dr. Lee will be responsible for developing and
implementing the scientific direction of Lorus. Dr. Lee received his Ph.D.
degree in Molecular Biology and Genetics from the University of Guelph and
completed a three-year post-doctoral training program at the University of
Michigan. He joined Lorus through the merger with GeneSense Technologies Inc.
in 1999, where he was a Research Scientist involved in the GeneSense
oligonucleotide therapeutics program. He has authored many scientific
publications and is also an author of numerous patents and conference
proceedings.
	    "I am delighted to promote these two experienced professionals to our
senior management team", said Dr. Aiping Young, Lorus' President and CEO.
"Their skills and knowledge will allow us to progress our novel anticancer
drugs towards commercialization and seize emerging opportunities to accelerate
the growth of our business."

	    About Lorus

	    Lorus is a biopharmaceutical company focused on the research and
development of novel therapeutics in cancer. Lorus' goal is to capitalize on
its research, preclinical, clinical and regulatory expertise by developing new
drug candidates that can be used, either alone, or in combination with other
drugs, to successfully manage cancer. Through its own discovery efforts and an
acquisition and in-licensing program, Lorus is building a portfolio of
promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto
Stock Exchange under the symbol LOR, and on the American Stock Exchange under
the symbol LRP.

	    Forward-looking Statements

	    This press release contains forward-looking statements within the meaning
of Canadian and U.S. securities laws. Such statements include, but are not
limited to, statements relating to: financings and corporate reorganizations,
the establishment of corporate alliances, the Company's plans, objectives,
expectations and intentions and other statements including words such as
"continue", "expect", "intend", "will", "should", "would", "may", and other
similar expressions. Such statements reflect our current views with respect to
future events and are subject to risks and uncertainties and are necessarily
based upon a number of estimates and assumptions that, while considered
reasonable by us are inherently subject to significant business, economic,
competitive, political and social uncertainties and contingencies. Many
factors could cause our actual results, performance, achievements or the
transactions described in this press release to be materially different from
any future results, performance, achievements or transactions described in
this press release, if at all, that may be expressed or implied by such
forward-looking statements, including, among others: the progress of
negotiations; our ability to obtain regulatory, security holder and other
approvals; our ability to obtain the capital required for research and
operations; the inherent risks in early stage drug development including
demonstrating efficacy; development time/cost and the regulatory approval
process; the progress of our clinical trials; our ability to find and enter
into agreements with potential partners; our ability to attract and retain key
personnel; changing market conditions; and other risks detailed from
time-to-time in our ongoing quarterly filings, annual information forms,
annual reports and annual filings with Canadian securities regulators and the
United States Securities and Exchange Commission.
	    Should one or more of these risks or uncertainties materialize, or should
the assumptions set out in the section entitled "Risk Factors" in our filings
with Canadian securities regulators and the United States Securities and
Exchange Commission underlying those forward-looking statements prove
incorrect, actual results may vary materially from those described herein.
These forward-looking statements are made as of the date of this press release
and we do not intend, and do not assume any obligation, to update these
forward-looking statements, except as required by law. We cannot assure you
that such statements will prove to be accurate as actual results and future
events could differ materially from those anticipated in such statements.
Investors are cautioned that forward-looking statements are not guarantees of
future performance and accordingly investors are cautioned not to put undue
reliance on forward-looking statements due to the inherent uncertainty
therein.

	    Lorus Therapeutics Inc.'s recent press releases are available through its
website at www.lorusthera.com. For Lorus' regulatory filings on SEDAR, please
go to www.Sedar.com. For SEDAR filings prior to July 10, 2007 you will find
these under the company profile for Global Summit Real Estate Inc. (Old
Lorus).

	    %SEDAR: 00025614EF          %CIK: 0000882361

	    /For further information: Lorus Therapeutics Inc., Dr. Aiping Young,
(416) 798-1200 ext. 379, ir(at)lorusthera.com/
	    (LOR. LRP)

CO:  Lorus Therapeutics Inc.

CNW 07:30e 05-MAY-08
-----END PRIVACY-ENHANCED MESSAGE-----